Shots:
- Regeneron has entered a strategic research collaboration with Parabilis to discover & develop multiple therapeutics using Parabilis’ Helicon peptide platform, with a focus on Antibody-Helicon Conjugates (AHCs)
- Regeneron will lead development, manufacturing, & global commercialization, while Parabilis will receive $125M, incl. $50M upfront & a $75M commitment toward its next equity financing, subject to conditions
- Parabilis is eligible for ~$2.2B in development, regulatory, & commercial milestone payments across 5 initial targets, plus tiered royalties up to low double-digit on future sales, with additional targets subject to option payments from Regeneron
Ref: Globenewswire | Image: Regeneron & Parabilis Medicines | Press Release
Related News: Telix Partners with Regeneron to Develop and Commercialize Radiopharmaceutical Therapies for Pain in a ~$2.1B
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
